OTCMKTS:ZLDPF Zealand Pharma A/S 2/20/2025 Earnings Report $50.26 0.00 (0.00%) As of 05/22/2026 12:18 PM Eastern ProfileEarnings HistoryForecast Zealand Pharma A/S EPS ResultsActual EPS-$0.59Consensus EPS -$0.78Beat/MissBeat by +$0.19One Year Ago EPSN/AZealand Pharma A/S Revenue ResultsActual Revenue$1.30 millionExpected Revenue$28.11 millionBeat/MissMissed by -$26.81 millionYoY Revenue GrowthN/AZealand Pharma A/S Announcement DetailsQuarterDate2/20/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsZealand Pharma A/S' next earnings date is estimated for Thursday, August 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Zealand Pharma A/S Earnings HeadlinesResolutions from Zealand Pharma's Extraordinary General Meeting 20261 hour ago | markets.businessinsider.comZealand Pharma - Transactions related to share buy-back program (week 21, 2026)1 hour ago | markets.businessinsider.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.May 26 at 1:00 AM | Porter & Company (Ad)Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 22, 2026 | americanbankingnews.comZealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)May 14, 2026 | markets.businessinsider.comZealand Pharma - Execution framework for share buy-back programMay 7, 2026 | markets.businessinsider.comSee More Zealand Pharma A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email. Email Address About Zealand Pharma A/SZealand Pharma A/S (OTCMKTS:ZLDPF) is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited. Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia. The company is also developing glepaglutide, a long‐acting GLP-2 analog for the management of short bowel syndrome, with ongoing clinical trials assessing its ability to reduce parenteral support dependency. Zealand has entered strategic collaborations with leading pharmaceutical firms to co‐develop and commercialize select programs, leveraging global regulatory and commercial expertise to accelerate patient access. Founded in 1998 and headquartered in Copenhagen, Zealand Pharma conducts research and development activities in Scandinavia while maintaining partnerships and licensing agreements that extend its reach to markets in Europe, North America and Asia. The company’s leadership, including CEO Emmanuel Dulac, brings together expertise in peptide science, clinical development and corporate strategy. Zealand Pharma’s dual listing on the Copenhagen Stock Exchange and OTC markets in the U.S. underscores its commitment to broad investor engagement and global growth.View Zealand Pharma A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AutoZone's Pullback Sets Up a Long-Term Buying OpportunityAST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in FocusPowerhouse Williams-Sonoma Heading to Fresh Highs in 2026Why BJ’s Wholesale Club Stock Could Be Ready for a ReboundRocket Companies Turns Around, But Mortgage Risk RemainsAfter NVIDIA, Broadcom's Earnings Are Next—Here's What to WatchRoss Stores Earnings Beat Sends Stock To New Highs Upcoming Earnings Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026)Canadian Imperial Bank of Commerce (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
